Skip to main content
SpringerLink
Log in

The 2006 Adrian Salter Lecture

Medicines Regulation and the Health of the Patient

  • Meeting Report
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

  2. The Lecture was followed by a discussion session.

References

  1. Medicines and Healthcare Products Regulatory Agency Committee on Safety of Medicines. Always read the leaflet: getting the best information with every medicine. Report of the Committee on Safety of Medicines Working Group on Patient Information. Norwich: The Stationery Office, 2005 [online]. Available from URL: http://www.mhra.gov.uk/home/idcplg?.IdcService=SS_GET_PAGE&odeId=511 [Accessed 2007 Apr 24]

    Google Scholar 

  2. Snell NJC. Human volunteer studies: safety considerations in an era of highly active biological agents: lessons from the Te Genero tragedy. Int J Pharm Med 2006; 20 (5): 293–6

    Article  Google Scholar 

  3. Suntharalingam G, Perry M, Ward S, et al. Cytokine storm in a phase I trial of the anti-CD28 monoclonal antibody TGN1412. New Eng J Med 2006; 355: 1018–28

    Article  PubMed  CAS  Google Scholar 

  4. United States Food and Drug Administration. Challenge and opportunity on the critical path to new medical products [report]. Rockville (MD): US Department Health & Human Services, 2004

    Google Scholar 

  5. Institute of Medicine of the National Academies. The future of drug safety [report]. Washington, DC: The National Academies Press, 2006

    Google Scholar 

  6. Fox AW. Report on drug safety and the US FDA by the Institute of Medicine. Int J Pharm Med 2006; 20 (5): 289–91

    Article  Google Scholar 

Download references

Acknowledgements

The views and ideas expressed by Professor Sir Alasdair in this lecture are not to be interpreted as representing any official statement by the Medicines and Healthcare Products Regulatory Agency (MHRA) or by Her Majesty’s Government. Foreign readers should note that the MHRA and the National Institute for Clinical Excellence (NICE) are separate and independent organisations.

No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Medicines and Healthcare Products Regulatory Agency (MHRA), London, England

    Alasdair Breckenridge (Chairman)

Authors
  1. Alasdair Breckenridge
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The Lecture is a bequest of Dr Adrian Salter, and is held annually under the auspices of the Society of Pharmaceutical Medicine. Dr Salter had a pivotal role in bringing the Society into existence, and was its founding secretary. This year’s lecture was delivered by Professor Sir Alasdair Breckenridge in the house of the Royal Society of Medicine, London, UK on 9th November 2006 and the manuscript was prepared with the assistance of Dr Tony Fox, the Consulting Editor of the International Journal of Pharmaceutical Medicine; graciously, the Lecturer also dined with the Society afterwards. The Society is now almost 20 years old, and next year’s Adrian Salter Lecture will be part of a larger anniversary celebration.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breckenridge, A. The 2006 Adrian Salter Lecture. Int J Pharm Med 21, 235–237 (2007). https://doi.org/10.2165/00124363-200721030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200721030-00006

Keywords

Search

Navigation